EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Silico Insight to Identify Potential Inhibitors of BUB1B from Mushroom Bioactive Compounds to Prevent Breast Cancer Metastasis

Divya Mishra, Ashish Mishra, Sachchida Nand Rai, Santosh Kumar Singh, Emanuel Vamanu, Mohan P Singh

Frontiers in Bioscience-Landmark · 27.07.2023 · 28 (7)

DOI: 10.31083/j.fbl2807151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 27.07.2023. Verfasst von Divya Mishra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Bioinformatics, University of Allahabad, 211002 Prayagraj, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Breast Neoplasms, Protein Serine-Threonine Kinases, Agaricales, Cell Cycle Proteins. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancer is one of the most common types of cancer among women worldwide, and its metastasis is a significant cause of mortality. Therefore, identifying potential inhibitors of proteins involved in breast cancer metastasis is crucial for developing effective therapies. BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B) is a key regulator of mitotic checkpoint control, which ensures the proper segregation of chromosomes during cell division. Dysregulation of BUB1B has been linked to a variety of human diseases, including breast cancer. Overexpression of BUB1B has been observed in various cancer types, and its inhibition has been shown to induce cancer cell death. Additionally, BUB1B inhibition has been suggested as a potential strategy for overcoming resistance to chemotherapy and radiation therapy. Given the importance of BUB1B in regulating cell division and its potential as a therapeutic target, the development of BUB1B inhibitors has been the focus of intense research efforts. Despite these efforts, few small molecule inhibitors of BUB1B have been identified, highlighting the need for further research in this area. In this study, the authors aimed to identify potential inhibitors of BUB1B from mushroom bioactive compounds using computational methods, which could ultimately lead to the development of new treatments for breast cancer metastasis.

Methods

This study has incorporated 70 bioactive compounds (handpicked through literature mining) of distinct mushrooms that were considered and explored to identify a suitable drug candidate. Their absorption, distribution, metabolism and excretion (ADME) properties were obtained to predict the drug-likeness of these 70 mushroom compounds based on Lipinski’s rule of 5 (RO5). Screening these bioactive compounds and subsequent molecular docking against BUB1B provided compounds with the best conformation-based binding affinity. The best two complexes, i.e., BUB1B-lepitaprocerin D and BUB1B-peptidoglycan, were subjected to molecular dynamic simulations. Both complexes were assessed for their affinity, stability, and flexibility in protein-ligand complex systems.

Results

The molecular dynamic (MD) simulation studies revealed that lepitaprocerin D has an energetically favorable binding affinity with BUB1B. Results showed that the formation of a hydrogen bond between residues ASN123 and SER157, and lepitaprocerin D had strengthened the affinity of lepitaprocerin D with BUB1B.

Conclusions

This study identified lepitaprocerin D as a potential and novel inhibitor for BUB1B that could be a plausible drug candidate for identifying and controlling the spread of breast cancer metastasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsProtein Serine-Threonine KinasesAgaricalesCell Cycle ProteinsProtein Kinase InhibitorsAntineoplastic AgentsHumansFemaleMolecular Docking SimulationNeoplasm MetastasisMolecular Dynamics SimulationComputer Simulation

Stichwörter der Autor:innen

ADMETBUB1Baneuploidylepitaprocerin Dmolecular dockingmolecular dynamics simulationtumorigenesis

Substanzen

Protein Serine-Threonine KinasesBUB1B protein, humanCell Cycle ProteinsProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Centre of Bioinformatics, University of Allahabad, 211002 Prayagraj, Uttar Pradesh, India.
  • Centre of Experimental Medicine and Surgery, Institute of Medical Sciences, Banaras Hindu University, 221005 Varanasi, Uttar Pradesh, India.
  • Faculty of Biotechnology, University of Agricultural Sciences and Veterinary Medicine, 011464 Bucharest, Romania.
  • Centre of Biotechnology, University of Allahabad, 211002 Prayagraj, Uttar Pradesh, India.

Zitieren

APA

Mishra, D., Mishra, A., Rai, S. N., Singh, S. K., Vamanu, E., & Singh, M. P. (2023). In Silico Insight to Identify Potential Inhibitors of BUB1B from Mushroom Bioactive Compounds to Prevent Breast Cancer Metastasis. Frontiers in Bioscience-Landmark, 28(7). https://doi.org/10.31083/j.fbl2807151

Vancouver

Mishra D, Mishra A, Rai SN, Singh SK, Vamanu E, Singh MP. In Silico Insight to Identify Potential Inhibitors of BUB1B from Mushroom Bioactive Compounds to Prevent Breast Cancer Metastasis. Frontiers in Bioscience-Landmark. 2023;28(7). doi:10.31083/j.fbl2807151

BibTeX
@article{Mishra2023,
  author = {Mishra, Divya and Mishra, Ashish and Rai, Sachchida Nand and Singh, Santosh Kumar and Vamanu, Emanuel and Singh, Mohan P},
  title = {In Silico Insight to Identify Potential Inhibitors of BUB1B from Mushroom Bioactive Compounds to Prevent Breast Cancer Metastasis},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2023},
  volume = {28},
  number = {7},
  doi = {10.31083/j.fbl2807151}
}
Kostenlos starten →